[ XXXX therapy with eculizumab: Spanish experience].

@entity2214 @entity1 @entity8190 @entity281 @entity7965 @entity7135 @entity2142 @entity715 @entity2131
BACKGROUND AND OBJECTIVES: @entity7965 ( @entity7965 ) is a rare acquired @entity2214 characterized by complement-mediated @entity2142 , @entity2131 and @entity715 . Eculizumab is a humanized monoclonal antibody that blocks the cytolytic component of the complement system by binding to complement C5. MATERIAL AND METHODS: We report the results of eculizumab treatment in 25 @entity7965 @entity1 from different centers in Spain. Statistical analysis was perfomed with a SPSS v15.0 software. RESULTS: Fifty-eight per cent of the @entity1 achieved transfusional independence after a median of 14 months. Transfusion requirements were reduced in 60% of the remaining cases. Fatigue resolved in 96% of the @entity1 and smooth muscle dystony-related symptoms in all cases. A single case of treatment-related @entity281 was observed. CONCLUSIONS: Eculizumab controls effectively @entity2142 and greatly improves clinical symptoms. The drug is safe and well tolerated, without significant adverse effects except @entity7135 . @entity1 with suboptimal response to treatment must be assessed for bone @entity8190 and extravascular haemolysis.
